Table 4.

Percentage difference in bone outcomes per 10 years of HRT use, unadjusted, and then adjusted for type of menopause, and additionally adjusted for current height (m) and weight (kg)

	Unadjusted			Model 2 Adjusted for type of menopause			Model 3 Adjusted for type of menopause, height and weight
	% diff	95% CI	p-value	% diff	95% CI	p-value	% diff	95% CI	p-value
Diaphysis CSA (n=603)	1.9	-0.4, 4.2	.1	1.8	-0.6, 4.2	.1	2.4	0.3, 4.5	.03
Medullary CSA (n=602)	-6.5	-12.2, -0.7	.03	-5.7	-11.7, 0.2	.06	-5.5	-11.4, 0.4	.07
Total vBMD (n=597)	3.3	-0.3, 6.8	.07	2.3	-1.3, 6	.2	3.0	-0.6, 6.7	.1
Trabecular vBMD (n=596)	4.0	-0.3, 8.3	.07	2.9	-1.6, 7.3	.2	3.8	-0.6, 8.2	.09
Cortical vBMD (n=604)	0.9	0.4, 1.5	.001	0.9	0.3, 1.5	.003	0.9	0.3, 1.5	.002
Polar SSI (n=604)	6.0	2.6, 9.3	<.001	5.4	1.9, 8.9	.003	6.3	3.1, 9.4	<.001
Spine L1-L4 aBMD (n=747)	4.0	1.4, 6.5	.002
Ceased naturally				5.3	2.1,8.5	.001	6.6	3.6,9.7	<.001
Ceased surgically				-1.4	-6.1,3.2	.5	0.9	-3.5,5.4	.7
Hip aBMD (n=742)	1.8	-0.4, 3.9	.1	0.7	-1.5, 3	.5	2.8	0.8, 4.7	.007

p-value=.02 for the interaction between type of menopause and length of HRT